Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.2 (market cap $26.68B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 2.6× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and Twist Bioscience Corp for 27 Days on average.
| SHY | TWST | |
|---|---|---|
Market Cap | $26.68B | $10.08B |
Volume | 4,077,691 | 4,229,037 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $205.00 |
52-Week Low | $81.05 | $25.45 |
Typical Hold Time | 63 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.20 with minimal daily movement (+0.05%), reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 per share provide income stability, though key financial ratios are unavailable for fundamental assessment. The bond ETF faces headwinds from rising Treasury yields and inflation concerns.
Outlook remains cautious as rising interest rates pressure bond ETFs, though SHY's short-term focus may offer relative safety. Key risks include prolonged high yields and economic uncertainty. Investment appeal hinges on income generation in a volatile rate environment, with technical weakness suggesting limited near-term upside.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
